NEWTOWN, Pa., Oct. 2, 2026 /PRNewswire/ -- EPAM Systems, Inc. (NYSE: EPAM), a leading digital transformation services and product engineering company, will host a conference call at 8:00 a.m. ET, on Thursday, November 5, 2026, to discuss its third quarter 2026 financial results. A news release containing these results will be issued before the call.

The conference call will be live on the EPAM website at https://investors.epam.com.

Please visit the website at least 15 minutes before the call to register for the event. For those who cannot attend the live webcast, a replay will be available in the Investor Relations section of the website.

About EPAM Systems, Inc.

EPAM (NYSE:EPAM) is a global leader in AI transformation engineering and integrated consulting, serving Forbes Global 2000 companies and ambitious startups. With over thirty years of expertise in custom software, product and platform engineering, EPAM empowers organizations to become AI-Native enterprises, driving measurable value from innovation and digital investments. Recognized by industry benchmarks and leading analysts as a leader in AI, EPAM delivers globally while engaging locally, making the future real for clients, partners, and employees. 

We are proud to be recognized by Forbes, Glassdoor, Newsweek, Time Magazine, Great Place to Work and kununu as a Most Loved Workplace around the world.

Learn more at www.epam.com and follow us on LinkedIn.

Forward-Looking Statements

This press release includes estimates and statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Our estimates and forward-looking statements are mainly based on our current expectations and estimates of future events and trends, which affect or may affect our business and operations. These statements may include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. Those future events and trends may relate to, among other things, developments relating to the war in Ukraine and escalation of the war in the surrounding region, political and civil unrest or military action in the geographies where we conduct business and operate, difficult conditions in global capital markets, foreign exchange markets, global trade, and the broader economy, the adoption and implementation of artificial intelligence technologies by EPAM and its clients, and the effect that these events may have on client demand and our revenues, operations, access to capital, and profitability. Other factors that could cause actual results to differ materially from those expressed or implied include general economic conditions, the risk factors discussed in the Company's most recent Annual Report on Form 10-K and the factors discussed in the Company's Quarterly Reports on Form 10-Q, particularly under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" and other filings with the Securities and Exchange Commission. Although we believe that these estimates and forward-looking statements are based upon reasonable assumptions, they are subject to several risks and uncertainties and are made based on information currently available to us. EPAM undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable.

SOURCE EPAM Systems, Inc.

Share this article

CME Group Suspends Plans to Launch 24/7 10-Barrel Crude Oil Contract

CHICAGO, Oct. 2, 2026 /PRNewswire/ -- Today, CME Group provided the following statement about its plans to suspend launch of a new 10-Barrel Crude Oil futures contract:

"Providing efficient, regulated markets that allow our clients to cost-effectively manage business risk is always our top priority at CME Group," said CME Group Chairman and Chief Executive Terry Duffy. "We created and planned to launch a 10-Barrel oil contract to provide a transparent, regulated alternative to the 24/7 oil contracts that other venues have introduced in the marketplace. Whether as onshore prediction markets or offshore perpetuals, which are illegal for U.S. participants but may be accessed despite their illegality via virtual private networks, these energy products already trade around the clock, primarily for retail participants.

"We had hoped to provide a safer, more transparent alternative, within the U.S. jurisdiction and CFTC oversight. However, based on extensive conversations with industry participants, we have determined that key constituents are concerned that introducing 24/7 trading in energy without further due diligence could create unintended consequences, possibly introducing additional risk in the marketplace.

"Therefore, we are withdrawing our filing to launch this product at this time. We hope the CFTC will address the inequity, reestablish the level playing field that has made U.S. financial markets the envy of the world, and ensure all derivatives products meet the standards the law requires, in compliance with the core principles of the Commodity Exchange Act."

As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals. The company offers futures and options on futures trading through the CMEGlobex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.

CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC ("S&P DJI"). "S&P®", "S&P 500®", "SPY®", "SPX®", US 500 and The 500 are trademarks of Standard & Poor's Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.

CME-G

SOURCE CME Group

Share this article

INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Allison Transmission Holdings, Inc. (NYSE: ALSN) ("Allison" or the "Company") announced the completion of its partial redemption of $100 million aggregate principal amount of its 4.750% Senior Notes due 2027 (the "notes") on September 30, 2026 (the "redemption date"), pursuant to its optional redemption right under the indenture governing the notes, dated as of September 26, 2017.

On the redemption date, the notes were redeemed at a redemption price of 100.00% of the principal amount thereof plus accrued and unpaid interest to, but not including, the redemption date. Following the completion of the partial redemption, $300 million aggregate principal amount of the notes remain outstanding.

About Allison

Allison (NYSE: ALSN) is a global leader in high-performance mobility and work solutions built for the needs of the modern industrial world. Allison operates through two business units: Allison Transmission and Allison Off-Highway Drive & Motion Systems. Headquartered in Indianapolis, Indiana, USA, the Company manufactures solutions which offer industry-leading value propositions across vital sectors such as infrastructure, mining, energy, agriculture, construction, transportation and national security. For over 110 years, Allison has been recognized as a reliable partner of choice, keeping essential industries moving anytime, in over 150 countries around the world.

SOURCE Allison Transmission Holdings Inc.

Share this article

The article outlines how planning around budget, timeline, and design ensures a successful home addition.

WILLIAMSVILLE, N.Y., Oct. 2, 2026 /PRNewswire/ -- What questions should homeowners ask before starting a home addition project?

HelloNation has published an article that provides the answer, featuring insights from Crystal Hincherick of Nathaniel's Construction.

The HelloNation article explains that careful planning is essential for any home addition project. Homeowners should begin by understanding how their goals, budget, and timeline align with the scope of work. Asking the right questions early helps homeowners avoid delays and ensures the finished addition meets both functional and aesthetic expectations.

Budget is one of the most important factors to address. The article highlights that homeowners should ask about total costs, including labor, materials, and permits. Understanding the full budget helps homeowners prepare for unexpected expenses and maintain financial control throughout the home addition project. Clear discussions about budget also help set realistic expectations from the start.

Timeline is another key consideration. The article explains that homeowners should ask how long each phase of the home addition project will take, from design to construction. A well-defined timeline helps homeowners plan for disruptions and anticipate potential delays. Establishing a clear timeline ensures the project progresses smoothly and stays on track.

Design integration is also critical. The article notes that homeowners should ask how the addition will connect with the existing structure. This includes structural considerations as well as visual consistency. Ensuring the home addition project blends seamlessly with the current home helps achieve a cohesive final result.

Materials selection is another important topic. The article emphasizes that homeowners should ask about the durability, cost, and maintenance of materials used in the project. Choosing the right materials impacts both the long-term value and performance of the addition. Understanding materials options helps homeowners make informed decisions that align with their budget and design goals.

Permits are an essential part of the process. The article explains that homeowners must confirm which permits are required and how they will be obtained. Securing the proper permits ensures the home addition project complies with local regulations and avoids costly delays. Discussing permits early helps streamline approvals and inspections.

Contractor experience and communication are also important. The article highlights that homeowners should ask about past projects, references, and how communication will be handled. Strong communication helps homeowners stay informed about the timeline, budget, and progress of the home addition project.

Potential challenges should also be discussed. The article notes that asking about how unexpected issues are handled helps homeowners understand the contractor's approach to problem-solving. Being prepared for challenges ensures the project can adapt without compromising quality or timeline.

The article concludes that asking the right questions about budget, timeline, materials, and permits helps homeowners plan a successful home addition project. With proper preparation, homeowners can ensure their project runs smoothly and delivers lasting value.

Questions to Ask Before Starting a Home Addition Project features insights from Crystal Hincherick, Expert Contractor of Williamsville, NY, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. This approval allows for the use of Jaypirca as a first-line treatment for appropriate patients.

"This approval is grounded in data from BRUIN CLL-313, which showed a significant delay in disease progression for pirtobrutinib compared to chemoimmunotherapy, along with safety and tolerability consistent with its established profile," said Jennifer A. Woyach, M.D., professor, hematologist-oncologist, and Director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. "Doctors can now consider pirtobrutinib for appropriate patients when initial therapy is needed, not just later in a patient's treatment journey. Given the efficacy and tolerability of modern targeted therapies – coupled with factors like age or comorbidity – many people diagnosed with CLL or SLL today may only receive one or two lines of therapy, making initial treatment choices critically important."

The labeling for Jaypirca contains warnings and precautions for infections, hemorrhage, cytopenias, cardiac arrhythmias, second primary malignancies, hepatotoxicity including drug-induced liver injury and embryo-fetal toxicity. See Important Safety Information below and full Prescribing Information for additional information, including dosing modifications.

Jaypirca, the first-and-only FDA-approved non-covalent BTK inhibitor, is a highly selective kinase inhibitor that utilizes a novel non-covalent binding mechanism to target the BTK pathway in patients with CLL/SLL.1,2

The FDA approval is based on results from the primary analysis of the BRUIN CLL-313 clinical trial, which were presented at the American Society of Hematology Annual Meeting and Exposition in December 2025 and published in The Journal of Clinical Oncology.3 BRUIN CLL-313 is the first prospective, randomized Phase 3 study to examine the efficacy and safety of a non-covalent BTK inhibitor in patients with previously untreated CLL/SLL without 17p deletion.

In BRUIN CLL-313, at a median follow-up of 28 months, the primary endpoint of Independent Review Committee (IRC)-assessed progression-free survival (PFS) was significantly improved with pirtobrutinib (n=141) compared to bendamustine plus rituximab (BR) (n=141) (HR=0.20 [95% CI, 0.11–0.37]; p0.0001), and the median PFS was not yet reached for pirtobrutinib compared to 33.5 months for BR.4 IRC-assessed overall response rate (ORR) was 94% (95% CI, 89–98) in the pirtobrutinib arm (complete response [CR]=13%; partial response [PR]=81%) and 81% (95% CI, 73–87) in the BR arm (CR=21%; PR=60%). In the BRUIN CLL-313 trial, adverse reactions (ARs) led to dose reductions in 3.6% and permanent discontinuation of Jaypirca in 4.3% of patients. Serious ARs occurred in 28% of patients who received Jaypirca. Serious ARs occurring in ≥3% of patients included pneumonia (5%). The overall safety profile, including rates of atrial fibrillation or flutter, for patients treated with pirtobrutinib in the BRUIN CLL-313 trial was consistent with previously reported trials across treatment settings.

"This additional approval for Jaypirca, based on BRUIN CLL-313, marks a significant step forward, expanding its potential to reach more patients who may benefit – this time as an initial treatment for certain previously untreated patients with CLL or SLL," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "This milestone underscores Jaypirca's versatility in the CLL continuum of care, from the first-line setting for appropriate patients to its valuable role in the relapsed or refractory post-covalent BTK inhibitor setting, reinforcing Jaypirca's broad applicability as a meaningful treatment option for people with CLL or SLL."

Jaypirca is the first-and-only non-covalent BTK inhibitor recommended by the National Comprehensive Cancer Network® (NCCN®).1,5,6,7 Jaypirca is Category 2A recommended for treatment-naïve adult patients with CLL/SLL without del(17p), recommended for older patients with cardiac comorbidities who may only need one lifetime treatment for CLL/SLL.8 Jaypirca is a Category 1 preferred option for adult patients with relapsed or refractory CLL/SLL who have previously been treated with a covalent BTK inhibitor. Please see full NCCN guidelines for more information.

Lilly is studying Jaypirca in CLL/SLL in multiple Phase 3 studies. Details on the trials can be found by visiting clinicaltrials.gov.

See Important Safety Information below and full Prescribing Information for additional information.

Click here to view the CLL infographic.

About the BRUIN Clinical Development Program

The BRUIN clinical development program comprises four positive Phase 3 studies evaluating pirtobrutinib across multiple lines of CLL/SLL:

- BRUIN CLL-313 is the first prospective, randomized Phase 3 study to examine the efficacy and safety of a non-covalent BTK inhibitor in patients with previously untreated CLL without 17p deletion. The BRUIN CLL-313 study is evaluating pirtobrutinib versus chemoimmunotherapy (BR) in patients with CLL/SLL without 17p deletion who have not been previously treated.

- BRUIN CLL-314 is the first head-to-head Phase 3 CLL trial to compare covalent and non-covalent BTK inhibitors in a BTKi-naïve population, which included relapsed and refractory and treatment-naïve patients. The BRUIN CLL-314 study is evaluating pirtobrutinib versus ibrutinib in patients with CLL/SLL who were either treatment-naïve, or who were previously treated and were BTK inhibitor-naïve.

- BRUIN CLL-321 is the first randomized Phase 3 study in CLL in which all patients were previously treated with a covalent BTK inhibitor. The BRUIN CLL-321 study is evaluating pirtobrutinib versus investigator's choice of idelalisib plus rituximab (IdelaR) or BR in covalent BTK inhibitor pre-treated patients with relapsed and refractory CLL/SLL.

- BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize a venetoclax-containing control arm. The BRUIN CLL-322 study is evaluating time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated CLL/SLL patients.

About BRUIN CLL-313

BRUIN CLL-313 (NCT05023980) is a Phase 3, global, randomized, open-label study of Jaypirca (pirtobrutinib) versus chemoimmunotherapy (BR) in people with CLL/SLL without 17p deletion who have not been previously treated. The trial enrolled 282 patients who were randomized 1:1 to receive pirtobrutinib (200 mg orally, once daily until disease progression or unacceptable toxicity) or BR per labeled doses. BR is a chemoimmunotherapy regimen used in the treatment of CLL. The primary endpoint is PFS as assessed by blinded IRC. Secondary endpoints include investigator and IRC-assessed ORR and duration of response (DoR), investigator-assessed PFS, overall survival (OS), time to next treatment (TTNT), safety and tolerability and patient-reported outcomes (PRO).

About Jaypirca (pirtobrutinib)

Jaypirca (pirtobrutinib, formerly known as LOXO-305) (pronounced jay-pihr-kaa) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), non-covalent inhibitor of the enzyme BTK, and is the first-and-only approved non-covalent BTK inhibitor binding to both wild-type and C481 mutated BTK.2 BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).9,10 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.

About Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CLL and SLL are forms of slow-growing non-Hodgkin lymphoma that develop from white blood cells known as lymphocytes.11 CLL is one of the most common types of leukemia in adults.11 In the U.S., CLL accounts for about one-quarter of the new cases of leukemia and there will be approximately 22,760 new cases of CLL diagnosed this year.11,12 SLL is identical to CLL from a pathologic and immunophenotypic standpoint, with the main difference between them being the location of the cancer cells.11 In CLL, the cancer cells are present in the blood, and in SLL, the cancer cells are found in the lymph nodes.11

INDICATIONS FOR JAYPIRCA (pirtobrutinib)

Jaypirca is indicated for the treatment of:

- Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.

- Adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion.

- Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION FOR JAYPIRCA (pirtobrutinib)

Infections: Fatal and serious infections (including bacterial, viral, fungal) and opportunistic infections occurred in Jaypirca-treated patients. Across all clinical trials, Grade ≥3 infections occurred (23%), most commonly pneumonia (13%); fatal infections (4.3%), sepsis (4.8%), and febrile neutropenia (3.3%) occurred.

NEW YORK, Oct. 2, 2026 /PRNewswire/ -- The American Institute of Chemical Engineers (AIChE) will recognize 16 leaders and innovators in chemical engineering with the 2026 Institute and Board of Directors' Awards. The honorees, selected for their significant contributions to research, education, industrial practice, and service to the profession, will be celebrated at the 2026 AIChE Annual Meeting, November 8-12, in Minneapolis, Minnesota.

The Institute and Board of Directors' Awards represent AIChE's highest honors, recognizing individuals whose work has advanced chemical engineering and benefited society.

Dr. Nicholas Peppas, Cockrell Family Regents Chair in Engineering, The University of Texas at Austin, will receive the F. J. and Dorothy Van Antwerpen Award for Service to AIChE. The award is sponsored by Dow.

Dr. Liang-Shih Fan, Distinguished University Professor and C. John Easton Professor in Engineering, The Ohio State University, will receive the Founders Award for Outstanding Contributions to the Field of Chemical Engineering.

Dr. Rong Yang, Associate Professor, Cornell University, will receive the Allan P. Colburn Award for Excellence in Publications by a Young Member of the Institute. The award is sponsored by DuPont de Nemours, Inc.

Dr. Samir Mitragotri, Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard University, will receive the Alpha Chi Sigma Award for Chemical Engineering Research. The award is sponsored by the Alpha Chi Sigma Educational Foundation.

Dr. M. Scott Shell, Professor of Chemical Engineering, University of California, Santa Barbara, will receive the Andreas Acrivos Award for Professional Progress in Chemical Engineering. The award is endowed by the AIChE Foundation.

Dr. Kenneth Hanley, Senior Vice President of Research & Development for 3M's Transportation & Electronics, will receive the Industry Leadership Award.

Dr. Theresa Whiting, Product Developer, 3M Abrasive Systems Division, will receive the Industrial Progress Award.

Dr. Kevin Seibert, Vice President, Engineering, Synthetic Molecule Design and Development, Eli Lilly and Company, will receive the Industrial Research and Development Award. The award is sponsored by AbbVie.

Dr. Ruilan Guo, Professor, Chemical and Biomolecular Engineering, University of Notre Dame, will receive the Institute Award for Excellence in Industrial Gases Technology. The award is sponsored by Air Products and Chemicals, Inc.

Dr. Alon McCormick, Professor, University of Minnesota, will receive the Institute Award for Service to Society and the Energy and Sustainability Award.

Dr. Richard Flagan, Irma and Ross McCollum/William H. Corcoran Professor of Chemical Engineering and Environmental Science and Engineering, California Institute of Technology, will receive the L.-S. Fan Award for Excellence in Contributions to Chemical Engineering Literature. The award is endowed by the AIChE Foundation.

Scott J. Herrmann, Engineering Fellow at Qnity Electronics Inc., will receive the Lawrence B. Evans Award in Chemical Engineering Practice. The award is endowed by the AIChE Foundation and supported by CACHE Corporation.

Dr. Norma Alcantar, Professor and Associate Dean for Research, College of Engineering, University of South Florida, will receive the Margaret Hutchinson Rousseau Pioneer Award for Lifetime Achievement by a Woman Chemical Engineer. The award is sponsored by Pfizer.

Dr. Vemuri Balakotaiah, Professor Hugh Roy and Lillie Cranz Cullen Distinguished University Chair, University of Houston, will receive the R. H. Wilhelm Award in Chemical Reaction Engineering. The award is sponsored by ExxonMobil Research & Engineering Company.

Dr. Doraiswami (Ramki) Ramkrishna, Harry Creighton Peffer Distinguished Professor, Purdue University, will receive the Warren K. Lewis Award for Chemical Engineering Education. The award is sponsored by ExxonMobil Research & Engineering Company.

Dr. Dionisios Vlachos, Unidel Dan Rich Energy Chair in Energy Professor of Chemical and Biomolecular Engineering, University of Delaware; Director, Catalysis Center for Energy Innovation (CCEI); and Director, Delaware Energy Institute (DEI), will receive the William H. Walker Award for Excellence in Contributions to Chemical Engineering Literature. The award is sponsored by Wiley.

The 2026 honorees have strengthened chemical engineering through their discoveries, innovation, education, and service," said Anne O'Neal, AIChE's 2026 President. "Their accomplishments reflect the imagination and ingenuity that continue to move our profession forward and shape what comes next. We are proud to recognize their leadership and lasting contributions.

For more information about AIChE awards, visit www.aiche.org/awards.

About AIChE — The Global Home of Chemical Engineers

AIChE is a professional society of more than 52,000 chemical engineers in over 128 countries. Its members work in corporations, universities and government using their knowledge of chemical processes to develop safe and useful products for the benefit of society. Through its varied programs, AIChE continues to be a focal point for information exchange on the frontiers of chemical engineering research in such areas as energy, sustainability, biological and environmental engineering, nanotechnology and chemical plant safety and security. More information about AIChE is available at www.aiche.org.

SOURCE American Institute Of Chemical Engineers

Share this article

Sky Elements Sets GUINNESS WORLD RECORDS for Most Drones Flown in One Week and Flies the Largest Drone Show in America

More than 71,000 drone flights over three nights in North Texas, capped by an 11,000-drone show, bring the nation's largest show title home to Sky Elements

DALLAS, Oct. 2, 2026 /PRNewswire/ -- Sky Elements, the leading drone show company in the United States, set two GUINNESS WORLD RECORDS titles during seven large-scale drone shows over three consecutive nights in Blue Ridge, Texas. Together with Damoda America, the company launched 71,207 drones in one week, the most ever recorded, including an 11,000-drone performance, the largest drone show ever flown in America.

The team also set the record for the largest aerial display of a mythical creature, flying 10,183 drones to shatter the previous mark of 2,247. The titles are Sky Elements' 18th and 19th world records.

"Sky Elements already performs on the world stage, from Formula 1 in Monaco to our September 11th Memorial in New York City," said Rick Boss, CEO of Sky Elements. "Until now, shows of this size have happened in Asia and the Middle East. This week, we proved an American team can fly them here at home, and we did it night after night."

From Sunday, Sept. 27, through Tuesday, Sept. 29, Sky Elements flew six 10,000-drone shows and one 11,000-drone show, surpassing the previous record of 55,939 drones flown in one week. Crews recharged and relaunched the fleet between flights, and an official Guinness World Records adjudicator verified each one.

Sky Elements pilots, engineers, and designers worked onsite with Damoda America to create original formations for every show, filling the Texas sky with a soaring eagle, a lion, turning gears, a dragon, Pegasus, Americana imagery, and scenes from deep space. Recreations of Noah's Ark and a black hole, followed by a UFO sequence, closed out the attempt.

"Flying more than 10,000 drones at a time repeatedly, night after night, takes an extraordinary team, and Damoda America was a true partner at every step," said Boss. "We thank them for their commitment to this effort and for helping us bring a show of this scale to American skies."

The record-week performance positions Sky Elements to deliver shows featuring 10,000 drones or more for sports leagues, municipalities, brands, and major events nationwide.

Link to media from the event: https://app.shade.inc/collection/88523209-dfdd-4d44-a645-c27cdf837d4d

Contact:

Gregg Elkin

Partner, Strategic Communications and Brand Alliances

The Uptown Agency

[email protected]

214.577.8843

About Sky Elements

Sky Elements is the largest drone light show company in the United States, known for producing record-setting and visually stunning drone performances. With a national team of FAA-certified pilots, artists, and producers, the company creates unforgettable experiences for some of the world's biggest brands and events - including appearances on America's Got Talent and 19 Guinness World Records titles. Sky Elements performs shows across all 50 states and internationally, pushing the boundaries of aerial entertainment. Their team specializes in turnkey, fully customized shows for communities, corporations, tourism boards, professional sports teams, and private events. Discover more at skyelementsdrones.com

SOURCE Sky Elements Drones

Share this article

The article explains how driver logs, black box data, and federal trucking regulations affect liability and compensation.

JANESVILLE, Wis., Oct. 2, 2026 /PRNewswire/ -- What evidence matters most in a truck accident case in Janesville?

HelloNation has published the answer in an article featuring insights from Attorney Steve Caya of Nowlan Injury Law.

The HelloNation article explains that a truck accident often involves more complex evidence than a typical car crash. Commercial vehicles are governed by federal trucking regulations, and proving liability may require reviewing multiple sources of documentation. In Janesville, early preservation of evidence is essential because key records can be lost or altered over time.

Driver logs are identified as one of the most important pieces of evidence in a truck accident case. These logs document hours of service, rest breaks, and routes taken before the collision. Violations of federal trucking regulations reflected in driver logs may indicate fatigue or negligence, which can directly affect compensation.

Maintenance records also play a significant role in determining responsibility. The article explains that maintenance records reveal whether inspections and repairs were completed as required. If maintenance records show delayed service or ignored mechanical issues, they may demonstrate that a truck accident resulted from preventable equipment failure.

Black box data provides another critical source of information. Also known as event data recorder information, black box data can reveal speed, braking activity, and other vehicle actions just before impact. In Janesville truck accident investigations, black box data often helps reconstruct the sequence of events and clarify disputed facts.

Company safety policies are equally relevant. The article notes that reviewing company safety policies can show whether proper training, supervision, and inspection procedures were followed. When company safety policies are poorly enforced or ignored, liability may extend beyond the driver to the trucking company itself.

Federal trucking regulations guide how these elements are evaluated. The article explains that violations related to hours of service, load limits, or vehicle maintenance can support claims of negligence. Understanding how federal trucking regulations apply to a specific truck accident helps shape the investigation and supports a claim for compensation.

Witness statements and photographs further strengthen the case. Images of skid marks, road conditions, and vehicle damage provide context that supports driver logs and maintenance records. In Janesville, combining physical evidence with black box data creates a more complete understanding of how the truck accident occurred.

Insurance companies often request information soon after a crash. The article advises caution when providing statements, especially before reviewing driver logs, maintenance records, and black box data. Organized documentation allows claimants to present clear evidence and pursue appropriate compensation.

The article also emphasizes the importance of acting quickly. Because federal trucking regulations require certain records to be maintained for limited periods, delays can jeopardize access to driver logs and maintenance records. Prompt action helps ensure that black box data and company safety policies are preserved for review.

In serious truck accident cases, multiple parties may share responsibility. The article explains that examining company safety policies alongside federal trucking regulations can reveal systemic issues that contributed to the crash. This broader investigation may increase the likelihood of recovering full compensation for injuries and property damage.

The article concludes that building a strong truck accident case in Janesville requires careful collection and preservation of evidence. Driver logs, maintenance records, black box data, and company safety policies all contribute to establishing liability. When supported by witness statements and guided by federal trucking regulations, this evidence strengthens claims and improves the ability to secure fair compensation.

What Evidence Matters Most in a Janesville Truck Accident Case? features insights from Steve Caya, Personal Injury Attorney of Janesville, WI, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

SCOTTSDALE, Ariz., Oct. 2, 2026 /PRNewswire/ -- TruTrade, a U.S.-based software company specializing in automated trading technology, continues to advance its trading platform with technology designed to automate both trade execution and ongoing position management for retail traders.

Advanced trading technology has historically been associated with professional trading operations and institutional market participants. As technology has evolved, TruTrade has focused on bringing sophisticated automation into a platform designed around the needs and experience of the individual trader.

Once activated, TruTrade's software is designed to execute and manage trades automatically according to predefined parameters. regardless of whether the market is up or down. This approach can reduce the amount of manual interaction required throughout a trading session and allows the technology to consistently follow its programmed trading methodology.

"Automation should go beyond simply telling a trader when something is happening in the market," said Brian Nutt, Co-Founder of TruTrade. "We've focused on developing technology that can handle execution and position management as part of a complete automated trading experience."

TruTrade's platform is also designed to reduce dependence on constant chart monitoring. By automating key elements of execution and management, users can utilize the technology without remaining tied to a trading screen throughout the entire market session.

The company continues to develop its automated trading ecosystem around usability, accessibility and increasingly sophisticated execution technology for retail market participants.

Prospective clients can also request access to recorded trading demonstrations showing TruTrade's technology operating during actual market sessions, providing a closer look at how automated execution and position management work together.

As technology continues to reshape the retail trading landscape, TruTrade remains focused on narrowing the gap between sophisticated trading automation and everyday accessibility.

For more information, visit https://trutrade.io

SOURCE TruTrade

Share this article

The article explores high-demand roles like registered nurse, medical assistant, and radiologic technologist across northern West Virginia.

WHEELING, W.Va., Oct. 2, 2026 /PRNewswire/ -- Which healthcare careers are growing fastest in northern West Virginia?

HelloNation has published the answer in an article featuring insights from Chelsea Gianni of West Virginia Junior College.

The HelloNation article explains that healthcare careers in northern West Virginia continue to expand as hospitals, clinics, and community health centers seek more trained professionals. Among the options are registered nurse, medical assistant, and radiologic technologist roles, each supported by training paths that combine online coursework with clinical training and/or preparation for licensing or certification.

Registered nurse positions remain among the most in-demand healthcare careers in northern West Virginia. The article notes that a registered nurse provides direct patient care, administers medications, and supports treatment plans in a range of medical settings. Preparation for this path often includes a hybrid program structure with online coursework, supervised clinical training, and the steps required for certification through licensure exams.

Medical assistant roles are also seeing strong demand. A medical assistant helps with both administrative and patient-care responsibilities, making this one of the more versatile healthcare careers available to students. The article highlights that many students pursue a hybrid program model that blends online coursework with hands-on clinical training so they can prepare for certification while managing other responsibilities.

Radiologic technologist careers are another major area of growth in northern West Virginia. A radiologic technologist performs imaging procedures that support diagnosis and treatment, and the article explains that these programs typically include online coursework alongside in-person clinical training. This combination helps students build practical skills while preparing for certification and professional expectations in imaging environments.

The article also points to other expanding healthcare careers, including licensed practical nurses and pharmacy technicians. Each path has its own licensing or certification requirements. Still, a hybrid program format helps students balance school, work, and family obligations while completing clinical training.

Growth across northern West Virginia is being driven by an aging population, expanding outpatient care, and rising patient demand. The article explains that students who complete the right training, gain clinical training experience, and earn certification are more likely to find stable employment and long-term advancement opportunities.

When evaluating healthcare careers, the article recommends comparing program length, certification expectations, and the quality of online coursework and clinical training opportunities. Students should also consider whether a hybrid program offers the flexibility and support needed to complete training successfully.

Throughout the discussion, the article presents insights from an Education Expert perspective, emphasizing that healthcare careers in northern West Virginia offer strong employment potential and meaningful work. Roles such as registered nurse, medical assistant, and radiologic technologist continue to stand out because of employer demand, accessible training pathways, and advancement opportunities.

The article concludes that students can make informed choices by comparing healthcare careers based on certification requirements, program structure, and local workforce demand. By combining online coursework with clinical training in a hybrid program, students in northern West Virginia can prepare for rewarding careers that meet growing regional healthcare needs.

Which Healthcare Careers Are Growing Fastest in Northern West Virginia? features insights from Chelsea Gianni, Education Expert of Wheeling, WV, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article